Valuation: Fluicell AB

Market Cap 41.49M 4.34M 3.77M 3.5M 3.23M 6.09M 415M 6.2M 16.24M 206M 16.31M 15.96M 693M P/E 2024
-1.1x
P/E 2025 -1.65x
Enterprise Value 39.22M 4.11M 3.57M 3.31M 3.06M 5.76M 392M 5.86M 15.36M 195M 15.43M 15.09M 655M EV / Sales 2024
0.71x
EV / Sales 2025 0.75x
Free-Float
75.27%
Yield 2024 *
-
Yield 2025 -
1 day+4.30%
1 week+0.32%
Current month+4.30%
1 month+4.30%
3 months+121.05%
6 months+270.59%
Current year+215.00%
1 week 27.6
Extreme 27.6
32.6
1 month 27.6
Extreme 27.6
37
Current year 7.65
Extreme 7.65
67.2
1 year 7.65
Extreme 7.65
67.2
3 years 7.45
Extreme 7.45
594.3
5 years 7.45
Extreme 7.45
12,145
10 years 7.45
Extreme 7.45
15,330
Manager TitleAgeSince
Chief Executive Officer 42 01/01/2023
Chief Tech/Sci/R&D Officer 46 01/01/2017
Director of Finance/CFO 56 01/07/2023
Director TitleAgeSince
Director/Board Member 46 02/01/2012
Chairman 61 01/01/2016
Director/Board Member 54 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+4.30%+0.32%+166.95%-93.84% 4.27M
-0.80%+5.16%-0.70%+12.87% 48.95B
-4.28%+14.68%+24.12%+6.25% 40.75B
+4.20%-0.01%+409.90%+619.01% 38.46B
-1.76%-1.77%+7.02%+49.85% 36.38B
+5.56%+11.70%+11.64%+51.50% 28.45B
-1.51%-1.59% - - 16.62B
-1.16%-4.51%+32.14%+128.50% 16.33B
-6.64%-3.11%-9.08%-34.36% 13.65B
-0.06%+3.75%+3.81%+9.62% 13.56B
Average -0.16%+5.46%+71.76%+83.27% 25.31B
Weighted average by Cap. -0.25%+7.20%+75.06%+125.70%

Financials

2024 2025
Net sales 5.35M 560K 487K 452K 417K 785K 53.48M 799K 2.09M 26.56M 2.1M 2.06M 89.32M 15.22M 1.59M 1.38M 1.29M 1.19M 2.23M 152M 2.27M 5.96M 75.57M 5.99M 5.85M 254M
Net income -15.51M -1.62M -1.41M -1.31M -1.21M -2.28M -155M -2.32M -6.07M -77.02M -6.1M -5.97M -259M -8.33M -873K -758K -704K -649K -1.22M -83.3M -1.24M -3.26M -41.37M -3.28M -3.2M -139M
Net Debt -15.92M -1.67M -1.45M -1.35M -1.24M -2.34M -159M -2.38M -6.23M -79.07M -6.26M -6.13M -266M -2.26M -237K -206K -191K -176K -332K -22.61M -338K -886K -11.23M -890K -870K -37.77M
Logo Fluicell AB
Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Company’s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.
Employees
11
Date Price Change Volume
30/07/26 SEK 31.50 +4.30% 1,201
29/07/26 SEK 30.20 -4.73% 3,539
28/07/26 SEK 31.70 +1.28% 1,547
27/07/26 SEK 31.30 0.00% 9,035
24/07/26 SEK 31.30 -0.32% 2,619
  1. Stock Market
  2. Stocks
  3. FLUI Stock